Pipeline & Innovation | Bioremedy Pharma

Bioremedy Pharma grows its portfolio by inbound licensing novel molecules, registering them with the SFDA and developing products with world class partners across Africa and the Middle East.

We are a partner of choice for global innovators looking to reach our region. Rather than discovering molecules from scratch, we identify promising therapies, navigate SFDA registration, and bring them to patients through our commercial and distribution strengths.

We scout and license innovative, clinically differentiated molecules from leading global and European partners to address unmet needs in our markets.

Our regulatory affairs team manages end to end SFDA registration and quality compliance, accelerating the path from agreement to availability.

We continually broaden our footprint across metabolic, neuropsychiatry, women's and men's health, baby care, dermatology and wound care.

Through partnered R&D with EU and Italian partners such as Ekuberg Pharma, Invent Farma, Lesvi and Neuraxpharm, we jointly develop and adapt products for the needs of Africa and the Middle East, combining global science with local insight.

Every product we bring to the region is chosen with the same disciplined lens, balancing clinical value, regional fit and long term reliability.

Therapies that address real unmet needs and offer a clear benefit to patients and clinicians in our markets.

Products that fit the disease burden, demographics and standards of care across Africa and the Middle East.

A strong quality and documentation foundation that supports a smooth path through SFDA registration.

Partners who can sustain consistent, quality supply so patients can depend on continuity of care.

Our portfolio expands across seven therapeutic areas that matter most to the region.